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Abstract
Background: Sexually transmitted and genital infections in pregnancy are associated with an increased risk of
adverse maternal and neonatal health outcomes. High prevalences of sexually transmitted infections have been
identified among antenatal attenders in Papua New Guinea. Papua New Guinea has amongst the highest neonatal
mortality rates worldwide, with preterm birth and low birth weight major contributors to neonatal mortality.
The overall aim of our study was to determine if a novel point-of-care testing and treatment strategy for the sexually
transmitted and genital infections Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV)
and Bacterial vaginosis (BV) in pregnancy is feasible in the high-burden, low-income setting of Papua New Guinea.
Methods: Women attending their first antenatal clinic visit were invited to participate. CT/NG and TV were tested using
the GeneXpert platform (Cepheid, USA), and BV tested using BVBlue (Gryphus Diagnostics, USA). Participants received
same-day test results and antibiotic treatment as indicated. Routine antenatal care including HIV and syphilis screening
were provided.
Results: Point-of-care testing was provided to 125/222 (56 %) of women attending routine antenatal care during the
three-month study period. Among the 125 women enrolled, the prevalence of CT was 20.0 %; NG, 11.2 %; TV, 37.6 %;
and BV, 17.6 %. Over half (67/125, 53.6 %) of women had one or more of these infections. Most women
were asymptomatic (71.6 %; 47/67). Women aged 24 years and under were more likely to have one or more STI
compared with older women (odds ratio 2.38; 95 % CI: 1.09, 5.21). Most women with an STI received treatment on the
same day (83.6 %; 56/67). HIV prevalence was 1.6 % and active syphilis 4.0 %.
Conclusion: Point-of-care STI testing and treatment using a combination of novel, newly-available assays was feasible
during routine antenatal care in this setting. This strategy has not previously been evaluated in any setting and offers
the potential to transform STI management in pregnancy and to prevent their associated adverse health outcomes.
Keywords: Antenatal, Pregnancy outcome, Molecular testing, Syndromic management, Low-middle-income country,
Genexpert, Point-of-care, STIs
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Background
Previous studies among antenatal women in lowresource settings have found high prevalences of
sexually transmitted and genital infections, particularly
Chlamydia trachomatis (CT), Neisseria gonorrhoeae
(NG), Trichomonas vaginalis (TV) and Bacterial
vaginosis (BV), that are readily curable with cheap antibiotics [1]. Untreated, these bacteria are associated
with an increased risk of preterm birth, low birth
weight, premature rupture of membranes and other
adverse maternal and neonatal health outcomes [1].
Papua New Guinea (PNG) has among the highest
neonatal mortality rates worldwide, with an estimated
23 neonatal deaths per 1,000 livebirths [2]. Preterm
birth and low birth weight are major contributors to
neonatal mortality; in PNG an estimated 16 % of all
infants are of low birth weight [3]. In addition, an estimated 15 infants per 1,000 births are stillborn [4].
Preliminary results from the country’s first biobehavioural survey of STIs in pregnancy (n = 765)
identified high prevalences of CT (23.1 %), NG
(13.8 %), and TV (24.1 %) [5]. Overall, 44 % of pregnant women had at least one of these infections [5].
Around 80 % of women with laboratory-confirmed CT,
NG or TV were asymptomatic and therefore would not
have been detected and treated using national STI syndromic management guidelines that are based on clinical
criteria alone, consistent with WHO recommendations
for routine care in low-income settings [6, 7].
The lack of affordable, timely, easy-to-use and accurate
STI tests that can be used at point-of-care has meant
that for the last two decades routine practice in many
low and middle-income countries (LMIC) has been
based on syndromic management. Recent advances in
STI diagnostics however may herald a new era in STI
diagnosis and management in such settings, although
this as yet is untested in a LMIC setting such as PNG.
The GeneXpert platform (Cepheid, Sunnyvale CA,
USA) provides fully automated, easy-to-use point-ofcare molecular tests for CT, NG and TV that are as accurate as laboratory-based nucleic acid amplification
tests (NAATs) [8]. This robust and portable platform has
already revolutionized the diagnosis and management of
tuberculosis in a number of LMIC [9] and is now being
used in PNG. Disposable single-use cartridges hold the
reagents for the simultaneous detection of CT and NG,
with a separate cartridge used for TV detection. Test results are available in 90 (CT/NG) and 60 (TV) minutes,
allowing for immediate management.
The platform requires specific training in test procedures, some infrastructure including reliable electrical
power or a backup generator, as well as modifications to
service provision and patient flow to allow for immediate treatment and contact tracing.
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The diagnosis of BV has until recently relied on skilled
microscopic examination and scoring of Gram stained
vaginal smears using Nugent or Amsel scores. The
BVBlue test (OSOM BVBlue Test, Gryphus Diagnostics,
USA) is a recently developed chromogenic test for the
diagnosis of BV that detects increased vaginal fluid sialidase activity in 10 min. It is the first robust point-ofcare test available for BV and has a sensitivity of 90 %
and specificity of 95 % compared to Nugent or Amsel
scoring [10].
In this paper we present findings from the first feasibility study of antenatal point-of-care testing and treatment of CT, NG, TV and BV using a combination of
GeneXpert CT/NG, TV and the BVBlue Test, provided
in a routine antenatal clinic setting. This research was
conducted in preparation for a large-scale field trial to
evaluate this same strategy to improve pregnancy outcomes in PNG and other high-burden, LMIC settings.

Methods
Study design and procedures

A descriptive feasibility study was undertaken at a
government-run urban antenatal clinic in Alotau, Milne
Bay Province, PNG, between August and December
2014. All nursing staff at the clinic (Nursing Officers,
Midwives and Community Health Workers) were
trained in all aspects of the study, including the pointof-care testing.
Women aged 18 years or over and attending their first
antenatal visit were invited to participate. Following
written informed consent, women were enrolled consecutively and assigned a unique alphanumeric study
identity (ID) number. Nursing staff conducted a short
face-to-face interview with each participant, during
which socio-demographic and sexual behaviour data
were collected.
Women received routine antenatal and providerinitiated HIV and syphilis screening, and haemoglobin
estimation. HIV testing was conducted using HIV rapid
tests at point-of-care (Alere Determine HIV-1/2;
followed by confirmatory Chembio Stat-Pak HIV-1/2),
as per national guidelines. Syphilis testing used a rapid
point-of-care screening test (SD Bioline anti-TP 3.0,
Alere, Germany) followed by a confirmatory laboratorybased rapid plasma reagin (RPR) test. Women with a
positive anti-TP plus a reactive RPR (any titre) test were
considered to have active syphilis.
Following instructions from the nursing staff, participants provided two self-collected, mid-cavity, vaginal
swabs for on-site testing: CT/NG and TV using the
GeneXpert platform; and BV using the BVBlue rapid test
assay. Testing was conducted by nursing staff supported
by the in-country investigator team. Women diagnosed
with any of these four infections were offered same-day
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antibiotic treatment in accordance with PNG STI management guidelines; risk-reduction counselling, and contact tracing was provided as necessary.
Data management and statistical methods

Study-specific case record forms (CRFs) were used to
record socio-demographic, sexual behaviour, obstetric
and clinical information. STI test results were automatically recorded in the GeneXpert laptop database by participant study ID number and were similarly recorded in
a paper-based laboratory test log. CRF data were entered
by study ID into a study-specific database without personal identifiers. Each day, all CRFs and test result log
entries were reviewed for completion and consistency by
the lead investigators. Clinical and STI test result data
were entered into a study-specific Excel database and all
electronic database entries validated against participant
study folders for accuracy.
Data were summarised as frequencies and percentages. Fisher’s exact test was used to compare statistical differences in outcomes of interest between
younger and older women (e.g. STI prevalences). Data
were analysed using Stata IC v14.0 (StataCorp LP,
Texas, USA). Due to the modest sample size, it was
not possible to conduct multivariate analysis to examine independent risk factors.

Results
Clinic staff were able to conduct point-of-care testing
with minimal supervision after one day of intensive
training. Interest in the study was high with nearly
women who attended antenatal clinic requesting to
participate. Due to a clinic schedule that allocates one
weekday to new antenatal attendances (resulting in
20–25 new visits on a single day); the availability of limited
testing facilities (one single, four-module GeneXpert machine) and the requirement to provide same-day test results, we were unfortunately unable to enrol all those who
asked to join. As such, 125 of the 222 (56 %) who attended
the clinic were enrolled. Given these limitations women
were enrolled as they presented to clinic, i.e. on a first
come, first served basis and were not selected in any way
by clinic staff or the research team. The integration of
study procedures into routine antenatal clinic activities resulted in an average of two hours additional waiting time
per woman.
Among the 125 women recruited, the median age was
24 years; around 75 % (81/107) of women attended in
the first or second trimester of pregnancy; and almost
half were primigravid (59/125; 47 %; Table 1).
Province of birth was considered significant so as to
identify what proportion of women had been born in the
study province (Milne Bay) and what proportion were
not, in order to look at differences in STI prevalence
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among these groups. ‘Other province’ includes all other
provinces in PNG (there are 22 in total). Due to small
numbers for each individual province we aggregated
these and present this as ‘Other province’ rather than individual provinces.
Six women (6/125; 5 %) had a previous history of
miscarriage, stillbirth or neonatal death. Based on
point-of-care test results, more than half of women
(67/125; 53.6 %) had any of CT, NG, TV or BV, among
whom 71.6 % (48/67) were asymptomatic. Overall, the
prevalence of CT was 20.0 %; NG, 11.2 %; TV, 37.6 %;
and BV, 17.6 %. The prevalence of HIV was 1.6 %, and
4.0 % of the women had active syphilis. Women aged
24 years or under were significantly more likely to have
any of CT, NG, TV or BV, compared with older women
(63.6 % vs. 42.4 %; odds ratio [OR] 2.38, 95 % confidence interval [CI]: 1.09, 5.21). Younger women with
genital symptoms were six times more likely to have an
infection compared with older women who had genital
symptoms (25.8 % vs. 5.1 %; OR 6.48, 95 % CI: 1.70, 36.0).
There were no significant differences between younger
and older women in sexual behavioural characteristics, past history of an STI, or current genital symptoms. Among the 67 women who had one or more of
CT, NG, TV or BV, there were no significant differences in sexual behavioural characteristics between
younger and older women.
Among the 34 women who reported genital symptoms at enrolment, around half (19/34; 55.9 %) had
any of CT, NG, TV or BV. Among the six women
who reported a previous adverse pregnancy outcome,
four had a history of stillbirth, of whom two had TV,
and one had CT, TV and BV in the current study. All
women received their test results the same day. Of
those with any STI or genital infection, 83.6 % (56/67) received same-day treatment.
The remaining 12.4 % (11/67) had to leave prior to receiving treatment due to family commitments or the
need to travel significant distances back to their homes
by foot or by bus. All women had received treatment
within one week. Partners in attendance at the clinic
were treated the same day. All women and their partners
diagnosed with an infection received treatment in accordance with PNG national guidelines [11]. Given the
resource limitations of this study, test of cure follow-up
was not possible. It will however be a part of future large
scale antenatal trials.

Discussion
Antenatal point-of-care STI testing and treatment using
a combination of novel, newly-available diagnostic tests
proved feasible when integrated as part of routine antenatal care in this setting. This is the first study in any
setting to evaluate the feasibility of this approach. The
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Table 1 Socio-demographic characteristics, sexual behaviour, obstetric history, genital symptoms and point-of-care test results
Total

≤24 years

≥25 years

N (%)

N = 66 (%)

N = 59 (%)

p value

Socio-demographic characteristics
Age, median (IQR:18-41years)
Province of birth

Marital Status

Level of education (N = 124)

24 years

21 years

30 years

100 (80.0)

54 (81.8)

46 (78.0)

Other province

25 (20.0)

12 (18.2)

13 (22.0)

Married

108 (86)

51 (77.3)

57 (96.6)

Single

17 (13.6)

15 (22.7)

2 (3.4)

p = 0.002

Never attended school

4 (3.2)

0 (0)

4 (6.7)

p = 0.032

Milne Bay Province

Only primary school

39 (31.2)

18 (27.3)

21 (35.6)

Secondary school

81 (65.3)

47 (71.2)

34 (57.6)

Tertiary education

24 (19.2)

9 (13.6)

15 (25.4)

Obstetric history
Parity (N = 124)

Primigravid

59 (47.6)

48 (72.8)

11 (18.6)

Para 1–3

46 (37.0)

17 (25.8)

29 (49.2)

p < 0.0001
p = 0.008

Para 4 or more

19 (15.3)

0 (0.0)

19 (32.2)

6 (4.8)

3 (4.5)

3 (5.1)

12 weeks or less

13 (11.2)

5 (7.6)

8 (13.6)

13–26 weeks

68 (63.5)

38 (57.6)

30 (50.1)

Previous miscarriage/stillbirth/perinatal/
neonatal death (N = 125)
Estimated gestational age at enrolment
based on LMP (N = 107)

27–36 weeks

24 (22.4)

9 (13.7)

15 (25.4)

More than 36 weeks

2 (1.9)

1 (1.5)

1 (1.7)

19 years

18 years

20 years

1 partner

37 (31.1)

20 (30.3)

17 (28.8)

2–3 partners

51 (42.9)

29 (43.9)

22 (37.2)

Sexual behaviour
Age at sexual debut, median (IQR: 13–31years)
Lifetime number of sexual partners (N = 119)

Sexual partners in previous month (N = 124)

Number of times had vaginal sex in the
last month (N = 122)

Condom use last sex (N = 124)

4–6 partners

21 (17.6)

11 (16.6)

10 (16.9)

7 or more partners

10 (8.4)

4 (6.1)

6 (10.2)

0

31 (25.0)

18 (27.3)

13 (22.0)

1

80 (64.5)

41 (62.1)

39 (66.1)

2 or more partners

13 (10.5)

6 (9.1)

7 (11.9)

0

36 (29.5)

22 (33.3)

14 (23.7)

1–2 times

28 (23.0)

11 (16.7)

17 (28.8)

3 times or more

32 (26.2)

17 (25.6)

15 (25.4)

More than once/unknown

26 (21.3)

15 (22.7)

11 (18.6)

Yes

29 (23.4)

12 (18.2)

17 (28.8)

No

95 (76.6)

54 (81.8)

41 (69.5)

31 (24.8)

16 (24.2)

15 (25.4)

28 (22.4)

15 (22.8)

13 (22.0)

Ever had sex for gifts/favours/money
Reported genital symptoms at enrolment
Previous STI/genital infection
Current genital symptoms

Any symptom

34 (27.2)

20 (30.3)

14 (23.7)

Vaginal dischargea

24 (19.2)

16 (24.2)

8 (13.6)

Genital sores

1 (0.8)

1 (1.5)

0 (0.0)

Abdominal paina

8 (6.4)

4 (6.1)

4 (6.8)

Itchinga

19 (15.2)

10 (15.1)

9 (15.3)
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Table 1 Socio-demographic characteristics, sexual behaviour, obstetric history, genital symptoms and point-of-care test results
(Continued)
Other symptomsb

6 (4.8)

4 (6.1)

2 (3.4)

Any STI

67 (53.6)

42 (63.6)

25 (42.4)

1 STI

39 (31.2)

22 (33.3)

17 (28.8)

2 or more STIs

28 (22.4)

20 (30.3)

8 (13.6)

STI test results

HIV

2 (1.6)

2 (3.0)

0 (0.0)

Active syphilisc

5 (4.0)

3 (4.5)

2 (3,4)

p = 0.017

p = 0.025

C. trachomatis (CT)

25 (20)

18 (27.3)

7 (11.9)

p = 0.032

N. gonorrhoeae (NG)

14 (11)

12 (18.2)

2 (3.4)

p = 0.009

T. vaginalis (TV)

47 (37.6)

31 (47.0)

16 (27.1)

p = 0.022

Bacterial vaginosis (BV)

22 (17.6)

11 (16.7)

11 (18.7)

Genital symptoms and 1 or more STI detected

19 (15.2)

16 (24.3)

3 (5.1)

p = 0.002

Genital symptoms but no STI detected

15 (12.0)

4 (6.1)

11 (18.6)

p = 0.031

14 women had multiple symptoms/b discharge, pus, “wetness”/canti-TP+ and RPR+, all titres

a

high interest shown in study participation and 100 %
completion of study procedures among those enrolled
suggest the intervention has a high level of acceptability,
but needs to be formally established. An important limitation was our inability to meet antenatal testing demand: we were only able to recruit around 56 % of those
who attended yet nearly all women expressed an interest
in joining the study. Future intervention studies and
demonstration projects should consider setting up more
than one four-module GeneXpert machine per clinic in
situations of high workload.
High prevalences of STIs and genital infections were
observed among pregnant women in this setting, particularly those aged 24 years or under. These findings
are consistent with our earlier research among antenatal
women in PNG [12, 13]. A minority of women (34/125;
27.2 %) in the current study reported genital symptoms
at enrolment, of whom around half had CT, NG, TV or
BV; whilst more than 70 % of women with one or more
of these curable infections were asymptomatic. These
findings suggest that STI syndromic management, based
on clinical presentation alone, is a poor strategy for the
detection and treatment of STIs among pregnant women
in this setting and underline the need for robust, easyto-use, timely, and accurate point-of-care tests.
In this pilot study, the cost-effectiveness of this new
and broad based POC testing approach was not examined in detail. A cluster randomised trial of antenatal
point-of-care testing and treatment to improve pregnancy outcomes is due to start in PNG in 2016 [13].
This trial will establish the efficacy, acceptability, costeffectiveness and health system requirements of the proposed test and treat strategy, and will inform future
international policy and practice on the diagnosis and
management of STIs in pregnancy.

Conclusions
With increased Genexpert device availability this integrated point of care testing strategy has the potential to
change the way STI’s in pregnancy are managed and reduce the number of associated adverse health outcomes
for antenatal women in Papua New Guinea.
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